MİRİLİ, C. Et Al. 2018. EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC). ASCO 2018 , (Chicago, United States Of America).

MİRİLİ, C., PAYDAŞ, S., BAĞIR KILIÇ, E., SEYDAOĞLU, G., OĞUL, A., BÜYÜKŞİMŞEK, M., ... YETİŞİR, A. E.(2018). EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC) . ASCO 2018, Chicago, United States Of America

MİRİLİ, CEM Et Al. "EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC)," ASCO 2018, Chicago, United States Of America, 2018

MİRİLİ, CEM Et Al. "EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC)." ASCO 2018 , Chicago, United States Of America, 2018

MİRİLİ, C. Et Al. (2018) . "EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC)." ASCO 2018 , Chicago, United States Of America.

@conferencepaper{conferencepaper, author={CEM MİRİLİ Et Al. }, title={EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC)}, congress name={ASCO 2018}, city={Chicago}, country={United States Of America}, year={2018}}